PASADENA, Calif.--(BUSINESS WIRE)--Calando Pharmaceuticals, a leading siRNA therapeutics company and a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), together with City of Hope (COH) and the UCLA Jonsson Cancer Center (UCLA), today announced that Calando, UCLA and COH are planning a broad-based Phase I clinical trial to begin later this year for Calando’s lead drug candidate, CALAA-01, a nanoparticle containing non-chemically modified siRNA and a transferrin protein targeting agent formulated with Calando’s RONDEL™ (RNA/Oligonucleotide Nanoparticle Delivery) technology.
